article Open AccessTop 1% cited
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Annals of Oncology · 2019 · Vol. 30(5) · pp. 672–705
Nicoletta Colombo✉(University of Milan)Cristiana Sessa(Ospedale San Giovanni Bellinzona)Andreas du Bois(Kliniken Essen-Mitte)Jonathan A. Ledermann(CRUK Lung Cancer Centre of Excellence)W. Glenn McCluggage(Belfast Health and Social Care Trust)Iain A. McNeish(Imperial College London)Philippe Morice(Institut Gustave Roussy)Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")Isabelle Ray‐Coquard(Centre Léon Bérard)Ignace Vergote(Cancer Institute (WIA))Thaïs Baert(Kliniken Essen-Mitte)I. Belaroussi(Institut Gustave Roussy)A. Dashora(Maidstone and Tunbridge Wells NHS Trust)Siel Olbrecht(Cancer Institute (WIA))François PlanchampDenis Querleu✉(Institut Bergonié)Thaïs Baert(Kliniken Essen-Mitte)Susana Banerjee(KU Leuven)I. Belaroussi(Institut Gustave Roussy)Paweł BlecharzIlan Bruchim(Institut Gustave Roussy)David Cibula✉(Institut Bergonié)Nicoletta Colombo✉(University of Milan)Nicole ConcinBen Davidson(KU Leuven)A. Dashora(Maidstone and Tunbridge Wells NHS Trust)Mojgan Devouassoux‐ShisheboranAndreas du Bois(Kliniken Essen-Mitte)Annamaria FerreroRosalind Glasspool(Institut Bergonié)Antonio González-Martı́nViola Heinzelmann‐Schwarz(KU Leuven)Florence JolyJ.W. KimFrédéric KridelkaJonathan A. Ledermann(University College London)Domenica Lorusso✉(Institut Bergonié)Sven� Mahner(Cancer Institute (WIA))W. Glenn McCluggage(Belfast Health and Social Care Trust)Iain A. McNeish(Imperial College London)Mikio MikamiMansoor Raza MirzaPhilippe Morice(Institut Gustave Roussy)Shibani Nicum(Cancer Institute (WIA))Siel Olbrecht(KU Leuven)Dearbhaile M. O’DonnellPatricia PautierFrançois PlanchampSandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")Denis Querleu✉(Institut Bergonié)Isabelle Ray‐Coquard(Centre Léon Bérard)Alexandros RodolakisJalid Sehouli(CRUK Lung Cancer Centre of Excellence)Fatih SelçukbırıcıkCristiana Sessa(Ospedale San Giovanni Bellinzona)Nilanchali SinghDavid S.P. TanD. Timmerman✉(Institut Bergonié)Germana Tognon(Cancer Institute (WIA))Jacobus van der Velden(University College London)Ignace Vergote(KU Leuven)Petronella O. WitteveenAlain G. Zeimet(Belfast Health and Social Care Trust)
Ovarian cancer diagnosis and treatmentEndometrial and Cervical Cancer TreatmentsPARP inhibition in cancer therapyMedicineDiseaseOvarian cancerOncologyPathologyCancerMolecular pathologyConsensus conferenceInternal medicineGene
MeSH terms
Clinical Trials as TopicCombined Modality TherapyFemaleHumansNeoplasm MetastasisNeoplasm Recurrence, LocalOvarian NeoplasmsBiomarkers, TumorSurvival RateNeoplasm Grading
Funding
- U.S. Department of Defense
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Teva Pharmaceutical Industries
- F. Hoffmann-La Roche
- Novocure
- Clovis Oncology
- Eisai
- European Society for Medical Oncology
- PharmaMar
- Medac
- Takeda Oncology
- Ignyta
- Cilag
Citations
1,130
FWCI
123.81
field-weighted impact
References
322
Percentile
100%
vs. same field & year
Citations per year
References
Distinct evolutionary trajectories of primary high‐grade serous ovarian cancers revealed through spatial mutational profiling
The Journal of Pathology · 2013 · 431 citations
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Gynecologic Oncology · 2015 · 310 citations
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
The Lancet Oncology · 2015 · 1,554 citations
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
Cancer · 2009 · 1,581 citations
Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
Annals of Surgical Oncology · 2006 · 418 citations
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer
The Journal of Pathology · 2001 · 780 citations
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study
Gynecologic Oncology · 2006 · 307 citations
A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot Study
Annals of Surgical Oncology · 2006 · 394 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.